P. Del Poggio

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Massimo Iavarone, Roberta D’Ambrosio, Alessandro Soria et al. · Journal of Hepatology · 2020 · 392 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +14

Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial

Giuseppe Bárbaro, Gabriella Di Lorenzo, G Belloni et al. · The American Journal of Medicine · 1999 · 72 citations

Pharmacy, Internal Medicine, Pharmacotherapy +16

Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone

G. Idéo, A. Bellobuono, Silvana Tempini et al. · European Journal of Gastroenterology & Hepatology · 1999 · 42 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia

A. D’Alessio, P. Del Poggio, Federico Bracchi et al. · Leukemia · 2020 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis

Pietro Lampertico, R. Soffredini, George Papatheodoridis et al. · Digestive and Liver Disease · 2014 · 23 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15